FibroGen

Yahoo Finance • 17 hours ago

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor signaling inhibitor (ASRI) and pre-chemotherapy setting FG-3180 to be evaluated in the... Full story

Yahoo Finance • 23 days ago

FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million

FibroGen, Inc. Total consideration for the sale of FibroGen China to AstraZeneca is approximately $220 million, a $60 million increase from initial guidance Successfully repaid term loan to Morgan Stanley Tactical Value, further simplifyi... Full story

Yahoo Finance • 28 days ago

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2... Full story

Yahoo Finance • last month

China State Administration for Market Regulation approves sale of FibroGen China to AstraZeneca

* FibroGen (NASDAQ:FGEN [https://seekingalpha.com/symbol/FGEN]) said on Monday that the China State Administration for Market Regulation has approved the sale [https://seekingalpha.com/pr/20203338-fibrogen-announces-approval-of-sale-of-f... Full story

Yahoo Finance • last month

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

FibroGen, Inc. Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved... Full story

Yahoo Finance • last month

FibroGen raises China sale guidance to $210M, extends cash runway into 2028 as Phase II prostate cancer trial advances

Earnings Call Insights: FibroGen, Inc. (FGEN) Q2 2025 MANAGEMENT VIEW * CEO Thane Wettig highlighted three main priorities: the pending sale of FibroGen China, the advancement of lead asset FG-3246 (a potential first-in-class antibody... Full story

Yahoo Finance • last month

Earnings call transcript: FibroGen Q2 2025 revenue falls short, stock drops

FibroGen Inc., with a market capitalization of approximately $34 million, reported its Q2 2025 earnings on August 11, revealing a significant earnings miss with an EPS of -$1.88 compared to the forecast of -$0.09. The company’s revenue als... Full story

Yahoo Finance • last month

These stocks are moving in today's after hours session

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] AFTER HOURS GAINERS TICKER CHANGE COMMENT ANY [https://www.chartmill.com/stock/qu... Full story

Yahoo Finance • last month

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 million... Full story

Yahoo Finance • 2 months ago

FibroGen Q2 2025 Earnings Preview

* FibroGen (NASDAQ:FGEN [https://seekingalpha.com/symbol/FGEN]) is scheduled to announce Q2 earnings results on Monday, August 11th, after market close. * The consensus EPS Estimate is $1.00 [https://seekingalpha.com/symbol/FGEN/earnin... Full story

Yahoo Finance • 2 months ago

FibroGen to Report Second Quarter 2025 Financial Results

SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also conduct a conference call on that day at... Full story

Yahoo Finance • 3 months ago

FibroGen to implement 1-for-25 reverse stock split; shares down 15%

* FibroGen (NASDAQ:FGEN [https://seekingalpha.com/symbol/FGEN]) will execute a 1-for-25 reverse stock split effective June 16, 2025, at 5:00 p.m. ET. * Trading on a split-adjusted basis will begin June 17, 2025. * The split aims to r... Full story

Yahoo Finance • 3 months ago

FibroGen Announces 1-for-25 Reverse Stock Split

SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Reverse Stock Split"), effective at 5:00 p.... Full story

Yahoo Finance • 4 months ago

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025. “Michael is a well-recognized biotech industry vete... Full story

Yahoo Finance • 5 months ago

FibroGen to Report First Quarter 2025 Financial Results

SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on that day at 5:00... Full story

Yahoo Finance • 6 months ago

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025. FibroGen’s managemen... Full story

Yahoo Finance • 6 months ago

FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology

FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancer Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC expected by mi... Full story

Yahoo Finance • 6 months ago

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close of sale of FibroGen China, cash runway extended into 2027 Initiation of the Pha... Full story

Yahoo Finance • 7 months ago

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call o... Full story

Yahoo Finance • 7 months ago

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 millionUpon close, FibroGen will repay its term loan to Morgan Stanley Tactical Value, f... Full story